Impact of influenza vaccination on the risk of SARS-CoV-2 infection in a middle-aged group of people. Issue 9 (2nd September 2021)

• Record Type: Journal Article
• Authors: Bozek, Andrzej; Kozłowska, Renata; Galuszka, Beata; Grzanka, Alicja
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 9(2021)
• Page Start: 3126
• Page End: 3130
• Publication Date: 2021-09-02
• Subjects: Vaccine -- immunotherapy -- comparative effectiveness -- influenza -- SARS-CoV-2; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.1913961
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Aims: An observational study of a retrospective cohort was performed to assess the impact of influenza vaccination (IV) on the risk of SARS-CoV-2 infection in a population of middle-aged people for 8 weeks after IV and compared with an unvaccinated group. Patients and methods: Data from 1098 middle-aged patients (53.7 ± 4.7 years) after IV and 1205 unvaccinated patients (50.1 ± 6.8 years) were analyzed based on medical documentation. The inclusion criteria were age between 40 − 60 years and IV in the period from 1−30 September 2020. The incidence of infection with SARS-CoV-2 was confirmed by PCR and the classification of ICD-10 (U07.1). Results and conclusions: After IV, patients had significantly fewer SARS-CoV–2 infections than the unvaccinated patients ( P = .017). The hazard ratio was 0.74 (95% CI: 0.54−0.89). IV may partially reduce the risk of SARS-CoV-2 infection.